Casirivimab/imdevimab
experimental anti-COVID-19 drug developed by Regeneron
Casirivimab/imdevimab, sold under the brand names REGEN‑COV and Ronapreve in various countries, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.
The most common side effects include allergic reactions, which include infusion related reactions, injection site reactions, brief pain, weakness and others.
On 13 December 2024, the U.S. Food and Drug Administration revised its authorizations for the use of REGEN-COV. Its authorized uses are for post-exposure prophylaxis (prevention) and for the treatment of COVID-19, with restrictions for age, weight, and other factors of clinical importance.
On 5 December 2025, the European Union withdrew its marketing authorisation for Ronapreve, because Roche had formally notified it of its decision to permanently discontinue the marketing of the product.
Medical uses
In the European Union, the combination is indicated for the treatment of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) who do not require supplemental oxygen and who are at high increased risk of progressing to severe COVID‑19; and for the prevention of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb).
Deployment
REGEN‑COV is manufactured at the Regeneron's manufacturing facility in Rensselaer, New York.
The public source identifies “Casirivimab/imdevimab” as experimental anti-COVID-19 drug developed by Regeneron. This brief keeps that definition visible, then builds a research path around Casirivimab, imdevimab and experimental.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Casirivimab/imdevimab”, the useful work is to connect “experimental anti-COVID-19 drug developed by Regeneron” to the records capable of establishing context and consequence.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Jun 10, 2026. The linked authority identifier is Q99328880. None of the 1 selected statements returned an explicit reference. The first chronological checks are 2024 and 2025.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Casirivimab/imdevimab”, its source revision and the description used here.
- Expand the search: follow Casirivimab/imdevimab primary sources, Casirivimab/imdevimab archive and Casirivimab research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Casirivimab/imdevimab”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Casirivimab/imdevimab” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.